3 Australian AI Stocks To Watch In November 2026

Australian interest rates are rising as the Bank of England lifts its benchmark to 4%, and central banks worldwide keep tightening to fight inflation. Higher borrowing costs can pressure many sectors, yet companies using artificial intelligence to streamline healthcare may still find demand relatively resilient. This article looks at three AI driven healthcare stocks from our Australian screener that could offer exposure to this long term shift in medical care.

These three stocks are just a starting sample from the Australian AI healthcare universe, with the full screen surfacing 4 more companies with equally compelling stories that are not covered below.

To size up that broader opportunity set quickly, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter, analyze, and identify the highest conviction plays that best match your risk profile.

ImExHS (ASX:IME)

ImExHS is tightly plugged into AI driven diagnostics through its cloud imaging platforms and teleradiology services, giving it a front row seat as hospitals look to turn raw scans and reports into trainable data for smarter, automated workflows.

"The quarterly release indiates the company is getting through to profitability and cashflow sustainability. They also understand the challenge now is to drive the software sales and revenue much faster in 2026."

What happens if one unseen pressure on that shift toward higher margin software tilts either strongly in its favour or against it?

If that pressure point matters to your thesis, the full narrative for ImExHS lays out how ImExHS could accelerate or stall as software economics reshape its path.

Singular Health Group (ASX:SHG)

Singular Health Group uses its 3DICOM platform and AI in the Cloud to turn raw scan data into richer imaging workflows that can support diagnostics, education, and telehealth style use cases across clinicians, researchers, and patients.

Singular Health Group generates about A$1.9 million from 3DICOM medical technology and has a market value of roughly A$72 million.

For Singular Health Group, the real interest is how its AI enabled imaging tools might translate from clever software into recurring infrastructure for payers and health systems.

"The Florida Medicaid Imaging Repository, backed by US$3m in state funding with about US$2.5m expected to relate to Singular Health technical delivery once definitive agreements are completed, introduces a new infrastructure revenue stream that could support both top line growth and a higher contribution margin as the platform is reused across programs."

What happens to that margin story if one key proof point either validates the savings case in full or falls materially short of expectations?

If that outcome could reset how you think about Singular Health Group, the full narrative for Singular Health Group outlines where margins might accelerate, stall, or be obscured by early contracts.

Artrya (ASX:AYA)

Artrya uses its Salix AI software to analyse coronary CT angiography scans and flag heart attack risk, generating A$0.03 million from AI driven CCTA image analysis technology in Australia and carrying a market value of about A$544 million.

Heart disease is an area where AI guided diagnostics can be life changing, and Artrya leans directly into that theme through Salix, positioning its software as a way to turn routine CCTA scans into earlier warning signs for coronary artery disease.

"The SAPPHIRE multicenter real world study, targeting 10,000 to 12,000 scans across six high volume US systems and led by a well known principal investigator, is set up to build clinical evidence and brand credibility. This can support hospital adoption and help sustain longer term revenue and earnings growth if outcomes are favourable."

What investors will really be watching is how one crucial assumption about future scan economics ultimately feeds through to returns on all that AI development spend.

If that economic assumption is what you care about most, the full narrative for Artrya shows how scan pricing, adoption pace, and capital needs could decouple or accelerate.

Seeking Alternatives Beyond AI Healthcare?

Fresh opportunities can move from quiet to flying under momentum faster than headlines catch up. Scan these ideas before the crowd while it matters and get in early.

• Target resilient cash generators by scanning the list of solid balance sheet and fundamentals (12 results) and see which operators still show sturdy finances while many investors remain distracted elsewhere.
• Consider potential compounding income streams by checking the 5 dividend fortresses and focus on high-yield payers before any renewed interest tightens entry points.
• Review structural demand in crucial metals by using the 16 top copper producer stocks and focus on producers that could matter most if supply remains tight.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com